terazosin
Sign in to saveAlso known as ABBOTT-45975, Hytrin®, Terazosine, 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine, Térazosine, Terazosina, Terazosinum
Research
1,055 papers- Terazosin.2006
- Terazosin for benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2002
- [Terazosin].Deutsche medizinische Wochenschrift (1946) · 1998
- Terazosin attenuates abdominal aortic aneurysm formation by downregulating Peg3 expression to inhibit vascular smooth muscle cell apoptosis and senescence.European journal of pharmacology · 2024
- Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.British journal of urology · 1992
via PubMed
Wikidata facts
- Mass
- 387.191
Show 5 more facts
- chemical formula
- C₁₉H₂₅N₅O₄
- canonical SMILES
- COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
- World Health Organisation international non-proprietary name
- terazosin
- defined daily dose
- 5
- Commons category
- Terazosin
Sources (8)
via Wikidata · CC0
~2 min read
Article
3 sectionsContents
- Synthesis
- Research on neuroprotective effects
- References
Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.
Common side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.